TABLE 4.
Other myokines secreted during exercise with function in ND not deciphered.
| Myokines | Effects in NDs | Exercise stimulation | Expression in muscle | Muscle to blood (during exercise) |
| CX3CL1 | √ (Subbarayan et al., 2022) | √ (Njerve et al., 2016; Hashida et al., 2021) | √ (Stromberg et al., 2016) | × |
| FGF2 | √ (Kumar et al., 2020; Rajendran et al., 2021; Zhu et al., 2021) | × | √ (Homer-Bouthiette et al., 2021; Mathes et al., 2021) | × |
| LIF | √ (Vela et al., 2016; Bi et al., 2020) | √ (Kapilevich et al., 2017) | √ (Zakharova et al., 2021) | × |
| Myostatin | √ (Bondulich et al., 2017; Abati et al., 2022) | √ (Allen et al., 2011; Zhou et al., 2021) | √ (Bergen et al., 2015) | × |
| Myonectin | × | √ (Otaka et al., 2018) | √ (Otaka et al., 2018) | √ (Otaka et al., 2018) |
| NGF | √ (Eyjolfsdottir et al., 2016) | √ (Arvidsson et al., 2018) | √ (Hayashi et al., 2011) | × |
| Humanin | √ (Matsuoka and Hashimoto, 2010; Yen et al., 2018) | √ (Woodhead et al., 1985; Gidlund et al., 2016) | √ (Woodhead et al., 1985) | × |
CX3CL1 (Fractalkine), CX3C chemokine ligand 1; FGF2, fibroblast growth factor 2; LIF, leukemia inhibitory facto; NGF, nerve growth factor.